Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has ...

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

Merck & Company ( (MRK) ) has released its Q3 earnings. Here is a breakdown of the information Merck & Company presented to its ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., and Dr. Joerg Koglin, senior vice president and head of ...

InProcess-LSP are a young organization, founded in 2014, they have since emerged as providers of groundbreaking process analytical technology for nanoparticle characterization. This article provides a ...

Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...

Outlook Reflects a Net Negative Impact of $0.24 per Share Related to Business Development Transactions With Curon Biopharmaceutical and Daiichi Sankyo Merck (NYSE: MRK), known as MSD outside the ...

Anyone crafting a bull case for the pharmaceutical giant Merck (NYSE: MRK) should include Keytruda as the company's best asset. The cancer drug has been Merck's top-selling medicine and its ...

Shares of Merck & Co. Inc. MRK inched 0.44% higher to $101.17 Thursday, on what proved to be an all-around mixed trading ...

Merck KGaA said it’s seeing the beginning of a post-Covid pandemic rebound in life sciences as it reaffirmed the group’s sales and profit guidance for the full year. The German science and ...